Samer Nachawati, DO
Internal Medicine · Mesquite, TXNPI 1073652806
Payments from drug & device makers
Across 144 payments — averaging $16,686 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.3M
- Eli Lilly$416K
- AstraZeneca$280K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$277K
- Alnylam Pharmaceuticals Inc.$60K
- Sanofi US Services Inc.$24K
- plus $1K from 18 others
Across 3 payments — averaging $65,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$197K
What the payments were for
- Food & beverage$1,08470%
- Education$47530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 59 | $1,342,832 |
| Eli Lilly | 2 | $416,492 |
| AstraZeneca | 14 | $280,299 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $277,384 |
| Alnylam Pharmaceuticals Inc. | 7 | $60,461 |
| Sanofi US Services Inc. | 1 | $23,900 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $475 |
| Sunovion Pharmaceuticals Inc. | 22 | $240 |
| GSK | 8 | $143 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $97 |
| Sumitomo Pharma America, Inc. | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Genentech USA, Inc. | 1 | $52 |
| Baxter Healthcare | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Amgen | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Bayer | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$2,402,771 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $71,292 |
| OzempicSemaglutide | 29 | $49,151 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $39,864 |
| MounjaroTirzepatide | 31 | $33,598 |
| LinzessLinaclotide | 36 | $26,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $25,563 |
| Spiriva RespimatTiotropium Bromide | 14 | $20,289 |
| TrulicityDulaglutide | 19 | $20,052 |
| Spiriva HandihalerTiotropium Bromide | 22 | $16,651 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $11,689 |
| FarxigaDapagliflozin Propanediol | 28 | $11,213 |
| EntrestoSacubitril/Valsartan | 11 | $9,234 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $9,129 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,857 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 156 | $7,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $14 | $53,65050 claims |
| Novo NordiskOzempic | $15 | $49,15129 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $143 | $48,72147 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $280,299 | $48,46583 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Mesquite
- Salma SaigerMesquite$16.1M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.